ArticleBone marrow transplantation2025

The BLIND study: blinatumomab and DLI approach for management of B-ALL relapse after allogeneic stem cell transplantation. A multicentric Italian experience.

S Giammarco et al.PubMed ↗Publisher ↗

No numbers read from the abstract.